Pfizer stock is trading around $24.25, close to the bottom of its 52-week range, and the headline figure drawing investors back is a 7.1% dividend yield. For a global drugmaker of Pfizer’s scale, that payout is unusually high and reflects how far the shares have fallen from pandemic-era highs.
The market’s central question is whether Pfizer is a discounted income opportunity or a value trap. Shares are down roughly 55% from their 2021 peak, and the company is now trying to replace lost COVID windfall sales while managing a multiyear patent cliff led by Eliquis.
That tension has left the stock range-bound. Bulls point to a low forward earnings multiple and a growing oncology franchise after the $43.4 billion Seagen acquisition, while bears see revenue erosion, pricing pressure, and a shrinking cushion around the dividend.
Key Facts
- Pfizer stock was trading at about $24.25, near its 52-week range of $23.11 to $28.75.
- The company pays an annual dividend of $1.72 per share, equal to a yield of roughly 7.1% at the current share price.
- Shares have fallen about 55% from their 2021 pandemic peak after revenue neared $100 billion in 2022.
- Pfizer bought Seagen for $43.4 billion in a deal that closed in December 2023 to expand its oncology platform.
- Pfizer reaffirmed 2026 guidance for revenue of $59.5 billion to $62.5 billion and adjusted earnings of $2.80 to $3.00 per share.
Pfizer stock
What happened is straightforward: Pfizer’s pandemic boom ended, but the company has not yet fully convinced the market that its next growth engine is ready to compensate. COVID vaccine and antiviral demand that once drove extraordinary sales has normalized sharply, leaving the company to rebuild around its core drug portfolio and a large oncology expansion.
Why it matters is that Pfizer remains a major benchmark name for dividend investors, healthcare funds, and value-oriented portfolios. At roughly 8 to 9 times forward adjusted earnings, the stock screens as cheap relative to many large pharmaceutical peers. But that discount exists for a reason. Eliquis, one of Pfizer’s biggest contributors, has already lost exclusivity in Europe as of May 2026, and the looming U.S. patent expiration could create a much larger earnings hole.
Who is affected goes well beyond income investors chasing yield. Portfolio managers focused on defensive sectors are watching whether Pfizer can stabilize earnings, protect its payout, and turn oncology into a durable growth driver. For competitors and healthcare investors, Pfizer’s transition also offers a broader read on how large drugmakers navigate the move from mature blockbusters to pipeline-led growth.
Pfizer’s investment case has become a race between a 7.1% dividend yield and the speed of its oncology rebuild against a fast-approaching patent cliff.
Why oncology is now the deciding factor
The Seagen acquisition is the clearest expression of Pfizer’s strategy. Management is betting that antibody-drug conjugates and a broader cancer pipeline can offset both fading COVID product revenue and losses tied to patent expirations. Pfizer has committed more than 40% of its research and development budget to oncology and is targeting a doubling of oncology revenue by 2030.
Early signs are constructive, though not yet decisive. The acquired oncology portfolio has been growing at better than 20% operationally, with products such as Padcev and Lorbrena posting strong gains. Pfizer has also described 2026 as a catalyst-heavy year, with around 20 pivotal study starts and eight major data readouts, giving the stock several potential re-rating events beyond quarterly earnings.
Implications for Investors
For income-focused investors, the dividend is the immediate attraction. A $1.72 annual payout backed by adjusted earnings guidance of $2.80 to $3.00 per share suggests coverage remains intact for now, even if it is not especially loose. The board’s declared third-quarter dividend and the company’s long history of uninterrupted payments support the argument that management will work hard to defend the payout.
For value investors, the low multiple offers potential upside if Pfizer can prove that non-COVID growth is sustainable. First-quarter 2026 results showed revenue of $14.45 billion and adjusted earnings of $0.75 per share, both ahead of expectations, with core non-COVID operations showing healthier momentum than the headline narrative suggests. If upcoming pipeline readouts or August 4 earnings strengthen confidence in that trend, the market could revisit the stock’s discount.
The risk, however, is that the yield is high because the underlying business remains under pressure. Eliquis contributes roughly $6 billion to $7 billion in annual Pfizer revenue, and a sharper-than-expected exclusivity loss in key markets would pressure both earnings and sentiment. Add drug-pricing pressure in the U.S. and Europe, plus competitive erosion in parts of the existing portfolio, and investors have a clear list of reasons the shares remain stuck near their lows.
The next phase for Pfizer stock will likely be shaped by two closely watched markers: whether oncology growth keeps accelerating and whether management can contain the earnings impact of the patent cliff. If those pieces fall into place, the current valuation may look overly pessimistic; if not, the market’s caution will appear justified.